Xanthine oxidoreductase and metabolic syndrome

Tian-lian YAN,Cheng-fu XU,You-ming LI
DOI: https://doi.org/10.3760/cma.j.issn.1673-4157.2013.03.012
2013-01-01
International Journal of Endocrinology and Metabolism
Abstract:Xanthine oxidoreductase (XOR) controls the rate limiting step of purine catabolism by converting xanthine to uric acid.Recent studies showed that the abnormal activity of XOR not only led to hyperuricemia and gout,but also actively participated in the development of metabolic syndrome.However,how XOR affects obesity,hypertension,atherosclerosis,diabetes and other metabolic syndrome related diseases remains unclear.Its possible mechanism includes regulating the transcription factors of adipogenesis,affecting the synthesis of uric acid,nitric oxide and reactive oxygen species,etc.XOR inhibitor such as allopurinol and febuxostat has a protective effect of the diseases mentioned above.These findings would provide new ideas for treatment of metabolic syndrome.
What problem does this paper attempt to address?